| 摘要 |
The present invention provides novel compounds of dinucleotide polyphosphates and the method of preventing or treating diseases or conditions associated with platelet aggregation. The method comprises administering systemically to a patient a pharmaceutical comprising a purinergic P2<SUB>tau </SUB>receptor antagonist, in an amount effective to elevate its extracellular concentration to bind to P2<SUB>tau </SUB>receptors and inhibit P2<SUB>tau </SUB>receptor-mediated platelet aggregation. Methods of systemic administration include injection by intravenous, intramuscular, intrasternal and intravitreal routes, infusion, transdermal administration, oral administration, rectal administration and intra-operative instillation.
|
